308 related articles for article (PubMed ID: 33667790)
21. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
22. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
[TBL] [Abstract][Full Text] [Related]
23. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
[TBL] [Abstract][Full Text] [Related]
24. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer.
Liu C; Qian X; Yu C; Xia X; Li J; Li Y; Xie Y; Gao G; Song Y; Zhang M; Xue H; Wang X; Sun H; Liu J; Deng W; Guo X
Cancer Lett; 2024 Apr; 586():216642. PubMed ID: 38278470
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
27. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
28. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Castagnoli L; Cancila V; Cordoba-Romero SL; Faraci S; Talarico G; Belmonte B; Iorio MV; Milani M; Volpari T; Chiodoni C; Hidalgo-Miranda A; Tagliabue E; Tripodo C; Sangaletti S; Di Nicola M; Pupa SM
Oncogene; 2019 May; 38(21):4047-4060. PubMed ID: 30705400
[TBL] [Abstract][Full Text] [Related]
29. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; Roden AC; Hirsch FR; Wistuba II; Pusztai L
Breast Cancer Res; 2019 Jun; 21(1):72. PubMed ID: 31196152
[TBL] [Abstract][Full Text] [Related]
30. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
31. PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
Alkaabi D; Arafat K; Sulaiman S; Al-Azawi AM; Attoub S
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047395
[TBL] [Abstract][Full Text] [Related]
32. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
33. [Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells].
Yu XR; Wen QS; Xiao Y; Tang R; Li FX; Shao WF; Yu YL; Xiong JB
Nan Fang Yi Ke Da Xue Xue Bao; 2018 May; 38(5):561-566. PubMed ID: 29891452
[TBL] [Abstract][Full Text] [Related]
34. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
Sasidharan Nair V; Toor SM; Ali BR; Elkord E
Expert Opin Ther Targets; 2018 Jun; 22(6):547-557. PubMed ID: 29702007
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
Stovgaard ES; Bokharaey M; List-Jensen K; Roslind A; Kümler I; Høgdall E; Nielsen D; Balslev E
Breast Cancer Res Treat; 2020 Jun; 181(3):553-560. PubMed ID: 32358635
[TBL] [Abstract][Full Text] [Related]
37. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R
Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of indoximod upon stimulation with pro-inflammatory cytokines in triple-negative breast cancer cells.
Guney Eskiler G; Bilir C
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):554-561. PubMed ID: 34314307
[TBL] [Abstract][Full Text] [Related]
40. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
Front Immunol; 2019; 10():757. PubMed ID: 31031757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
